Skye Bioscience, Inc. (SKYE)

US — Healthcare Sector
Peers: RSPI  IBIO  STOK  FDMT  KTTAW  NVEC  VECO  ALTI  MFIC 

Automate Your Wheel Strategy on SKYE

With Tiblio's Option Bot, you can configure your own wheel strategy including SKYE - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol SKYE
  • Rev/Share 0.0
  • Book/Share 1494.2621
  • PB 0.0026
  • Debt/Equity 0.007
  • CurrentRatio 11.8485
  • ROIC -0.0004

 

  • MktCap 122078536.0
  • FreeCF/Share -232.3703
  • PFCF -0.0132
  • PE -0.014
  • Debt/Assets 0.0064
  • DivYield 0
  • ROE -0.7483

 

  • Rating B
  • Score 3
  • Recommendation Neutral
  • P/E Score 1
  • DCF Score 4
  • P/B Score 5
  • D/E Score 4

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
Initiation SKYE William Blair -- Outperform -- -- Feb. 28, 2025
Initiation SKYE Scotiabank -- Sector Outperform -- $20 Sept. 30, 2024
Initiation SKYE JMP Securities -- Mkt Outperform -- $15 Sept. 10, 2024

News

Skye Bioscience Shares Nimacimab “Anatomy of Progress” Video Series and Highlights Preclinical CB1 Antibody Data Presented at the American Diabetes Association's 85th Scientific Sessions
SKYE
Published: June 23, 2025 by: GlobeNewsWire
Sentiment: Neutral

SAN DIEGO, June 23, 2025 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biotechnology company focused on unlocking new therapeutic pathways for obesity and other metabolic health disorders, today announced the debut of its “Anatomy of Progress” nimacimab development update video series and availability of presentations related to the development of its anti-obesity drug, nimacimab, presented in multiple forums at the American Diabetes Association's (ADA) 85th Scientific Sessions held June 20-23, 2025, in Chicago, Illinois. The presentations are accessible at the following link.

Read More
image for news Skye Bioscience Shares Nimacimab “Anatomy of Progress” Video Series and Highlights Preclinical CB1 Antibody Data Presented at the American Diabetes Association's 85th Scientific Sessions
3 Stocks Targeting Weight Loss Market With Cannabinoid-Based Therapies
CRBP, NVO, SKYE
Published: May 23, 2025 by: Zacks Investment Research
Sentiment: Positive

NVO, CRBP and SKYE are tapping into the booming obesity market with novel CBD-based therapies, offering alternatives amid intensifying GLP-1 competition.

Read More
image for news 3 Stocks Targeting Weight Loss Market With Cannabinoid-Based Therapies

About Skye Bioscience, Inc. (SKYE)

  • IPO Date 2014-11-26
  • Website https://skyebioscience.com
  • Industry Biotechnology
  • CEO Punit S. Dhillon
  • Employees 16

Skye Bioscience, Inc., a biopharmaceutical company, discovers, develops, and commercializes cannabinoid-based molecules for the treatment of infectious diseases. The company's lead product candidate is SBI-100, which is in Phase I trials for the treatment of glaucoma and ocular hypertension. It is also developing SBI-200 that is in preclinical trials to treat and manage various eye diseases, including uveitis, dry eye syndrome, macular degeneration and diabetic retinopathy. The company was formerly known as Emerald Bioscience, Inc. and changed its name to Skye Bioscience, Inc. in January 2021. Skye Bioscience, Inc. was founded in 2012 and is headquartered in San Diego, California.